SCHEMBL8926

SCHEMBL8926

COc1cccc(CN)c1F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.52
IDO1 P14902 3/20 0.47
HTR2A P28223 2/20 0.46
HTR2C P28335 1/20 0.46
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA4 P22748 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
AOC3 Q16853 1/20 0.42
RPS6KA1 Q15418 1/20 0.42
CHRM2 P08172 1/20 0.41
CHRM1 P11229 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29792655 1.00 TAAR1 (0.52) TAAR1IDO1HTR2AHTR2CALDH1A1
Bromide SCHEMBL15741709 0.98 TAAR1 (0.50) TAAR1IDO1HTR2AHTR2CALDH1A1
Hydrochloric Acid SCHEMBL919638 0.98 TAAR1 (0.50) TAAR1IDO1HTR2AHTR2CALDH1A1
SCHEMBL17583898 0.86 TAAR1 (0.67) TAAR1HTR2AHTR2CCD274
SCHEMBL12525776 0.83 TAAR1 (0.53) TAAR1IDO1HTR2AHTR2CL3MBTL1
SCHEMBL855047 0.83 HTR2A (0.39) TAAR1HTR2AHTR2CGAAMAPT
SCHEMBL172225 0.83 HTR2A (0.46) TAAR1IDO1HTR2AHTR2CMAPT
SCHEMBL17351757 0.82 IDO1 (0.46) TAAR1IDO1HTR2AHTR2CALDH1A1
SCHEMBL422832 0.82 HTR2A (0.44) TAAR1IDO1HTR2AHTR2CALDH1A1
SCHEMBL3533385 0.82 HTR2A (0.44) TAAR1IDO1HTR2AHTR2CALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115619-A1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE GILEAD SCIENCES, INC. 2025-04-10 US disclosed
US-12227520-B2 Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use GILEAD SCIENCES, INC. (US) 2025-02-18 US disclosed
US-12221441-B2 Plasma kallikrein inhibitors and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-02-11 US disclosed
EP-4477220-A2 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF Takeda Pharmaceutical Company Limited (JP) 2024-12-18 EP disclosed
US-20240300936-A1 PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS AVELOS THERAPEUTICS INC. (KR) 2024-09-12 US disclosed
EP-4031547-B1 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2024-07-17 EP disclosed
EP-4031547-B1 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2024-07-17 EP disclosed
EP-4352049-A1 PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS Avelos Therapeutics Inc. (KR) 2024-04-17 EP disclosed
CN-117529476-A Preparation of substituted 1, 2-diamino heterocyclic derivatives and their use as medicaments 亚飞络思制药公司 2024-02-06 CN disclosed
US-20230391773-A1 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-12-07 US disclosed
WO-2009157527-A1 BENZOTHIAZOLE CARBOXAMIDES AS FUNGICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-12-30 WO disclosed
WO-2009157527-A1 BENZOTHIAZOLE CARBOXAMIDES AS FUNGICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-12-30 WO disclosed
WO-2009157528-A1 BENZOTHIAZOLE CARBOXAMIDES AS FUNGICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-12-30 WO disclosed
WO-2009107764-A1 COMPOSITION FOR AGRICULTURAL USE FOR CONTROLLING OR PREVENTING PLANT DISEASES CAUSED BY PLANT PATHOGENS 住友化学株式会社 (JP) 2009-09-03 WO disclosed
WO-2009093637-A1 AMIDE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-07-30 WO disclosed
WO-2009093640-A1 AMIDE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-07-30 WO disclosed
WO-2009069792-A1 AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-04 WO disclosed
WO-2009069792-A1 AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-04 WO disclosed
WO-2009051086-A1 N-BENZYL QUINOLINE-6-CARBOXAMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-04-23 WO disclosed
WO-2009051086-A1 N-BENZYL QUINOLINE-6-CARBOXAMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250115619-A1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE ZYX, CCNY, NCAPD3 TAAR1 4772/4885IDO1 1079/4885HTR2A 3531/4885
US-12227520-B2 Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use ZYX, CCNY, XDH TAAR1 4767/4885IDO1 1021/4885HTR2A 3429/4885
US-12221441-B2 Plasma kallikrein inhibitors and uses thereof KLKB1, KLK1, KLK5 TAAR1 4215/4885IDO1 2396/4885HTR2A 4331/4885
US-20240300936-A1 PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS MAST1, MAST3, MAST4 TAAR1 4029/4885IDO1 3658/4885HTR2A 2563/4885
US-20230391773-A1 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF KLKB1, KLK1, KLK5 TAAR1 4215/4885IDO1 2396/4885HTR2A 4331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.